157 related articles for article (PubMed ID: 10717525)
1. p53-regulated GML gene expression in non-small cell lung cancer. a promising relationship to cisplatin chemosensitivity.
Higashiyama M; Miyoshi Y; Kodama K; Yokouchi H; Takami K; Nishijima M; Nakayama T; Kobayashi H; Minamigawa K; Nakamura Y
Eur J Cancer; 2000 Mar; 36(4):489-95. PubMed ID: 10717525
[TBL] [Abstract][Full Text] [Related]
2. GPI-anchored molecule-like protein (GML) expression in non-small cell lung cancer (NSCLC).
Komiya T; Hirashima T; Kikui M; Fukuoka M; Ohno A; Kawase I
Anticancer Res; 1999; 19(5B):4315-9. PubMed ID: 10628393
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical p53 protein status in nonsmall cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs.
Higashiyama M; Kodama K; Yokouchi H; Takami K; Doi O; Kobayashi H; Tanisaka K; Minamigawa K
J Surg Oncol; 1998 May; 68(1):19-24. PubMed ID: 9610658
[TBL] [Abstract][Full Text] [Related]
4. [The importance of p53 and ras mutation as predictive markers for adjuvant chemotherapy in non-small-cell lung cancer].
Hirai Y; Shimizu Y; Oura S; Yoshimasu T; Ota F; Nakamura R; Naito K; Nishiguchi H; Hashimoto S; Okamura Y
Gan To Kagaku Ryoho; 2012 Mar; 39(3):381-4. PubMed ID: 22421763
[TBL] [Abstract][Full Text] [Related]
5. Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro.
Guntur VP; Waldrep JC; Guo JJ; Selting K; Dhand R
Anticancer Res; 2010 Sep; 30(9):3557-64. PubMed ID: 20944137
[TBL] [Abstract][Full Text] [Related]
6. The potential clinical value of GML and the p53 gene as a predictor of chemosensitivity for colorectal cancer.
Hashimoto Y; Ueda K; Minami K; Watatani M
Int J Clin Oncol; 2001 Apr; 6(2):90-6. PubMed ID: 11706756
[TBL] [Abstract][Full Text] [Related]
7. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
8. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of Merm1/Wbscr22 attenuates sensitivity of H460 non-small cell lung cancer cells to SN-38 and 5-FU without alteration to p53 expression levels.
Yan D; Zheng X; Tu L; Jia J; Li Q; Cheng L; Wang X
Mol Med Rep; 2015 Jan; 11(1):295-302. PubMed ID: 25352209
[TBL] [Abstract][Full Text] [Related]
10. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells.
Lai SL; Perng RP; Hwang J
J Biomed Sci; 2000; 7(1):64-70. PubMed ID: 10644891
[TBL] [Abstract][Full Text] [Related]
11. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
12. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
Ma LY; Xie XW; Ma L; Pang JL; Xiong XM; Zheng HD; Shen XL; Wen ZG; Wang HY
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway.
Xia Y; He Z; Liu B; Wang P; Chen Y
Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
15. TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells.
Mohammed Ael S; Eguchi H; Wada S; Koyama N; Shimizu M; Otani K; Ohtaki M; Tanimoto K; Hiyama K; Gaber MS; Nishiyama M
Exp Lung Res; 2012 Nov; 38(9-10):463-74. PubMed ID: 23098063
[TBL] [Abstract][Full Text] [Related]
16. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
17. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
19. Restoration of wild-type p53 activity enhances the sensitivity of pleural metastasis to cisplatin through an apoptotic mechanism.
Riva CM
Anticancer Res; 2000; 20(6B):4463-71. PubMed ID: 11205289
[TBL] [Abstract][Full Text] [Related]
20. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
